Patent represents broadened claims protecting Norak’s
proprietary Transfluor® technology

August 27, 2003 – Research Triangle Park, NC - Norak Biosciences, Inc. announced today an additional patent issued covering compositions and methods that protect its Transfluor® technology in Australia. The newly issued patent claims compositions and cells expressing any labeled beta-arrestin, an intracellular protein, and its use, that track the natural movement of arrestin protein. It is expected that similar claims will issue worldwide including United States, Europe, Canada and Japan covering similar constructs, and also covering other biologically active forms of arrestin.

Norak’s Transfluor® technology is a patented, universal GPCR drug discovery technology designed to be the most accurate method for discovering ligands for GPCR targets, whether known or orphan. Transfluor® was exclusively licensed in 1999 by Norak from technology developed at Duke University Medical Center and represents the combined research into GPCR signaling pathways over several decades by Norak’s scientific founders, Drs. Marc Caron, Robert Lefkowitz, and Larry Barak.

“We are pleased to have exclusive rights for compositions and methods involving any labeled beta-arrestin,” commented Dr. Roger. D. Blevins, Norak’s President and CEO. “We are aggressively pursuing this scope of claims as well as other improvements for Transfluor® worldwide.”

About Norak Biosciences, Inc.
Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company. Norak is utilizing its proprietary Transfluor® technology to become a worldwide leader in the discovery and development of drugs that regulate G protein-coupled receptors. For more information about Norak Biosciences, Inc., please visit the Company’s website at http://www.norakbio.com.

For further information, contact:
Terry E. Willard
Executive Vice President
Norak Biosciences, Inc.
7030 Kit Creek Road
Morrisville, NC 27560
Phone: 919-248-8000 ext. 8804
Fax: 919-248-8033
Email: twillard@norakbio.com

Back to Portfolio News